1. India Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Everest Organics Ltd.

Everest Organics Ltd.

BBSE:EVERESTO
222.50
INR
-7.50
(-3.26%)
5.42EPS
46.15P/E
2.43BMarket Cap
Everest Organics Ltd.
BSE:EVERESTO
(Bombay Stock Exchange)

Recent

price

222.50

P/E

ratio

46.15

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
104.05
114.1
297.29
133.41
140.21
194.9
209
226.91
250.12
231.07
240.88
164.23
201.69
196.68
Revenue per Share
0.94
1.78
0.54
1.69
2.14
9.39
13.62
17.14
1.43
-0.23
0.17
-1.33
5.7
5.42
Basic EPS, GAAP
- -
1.36
0.51
2.67
1.33
2.22
3.15
8.35
-4.27
6.17
3.66
-11.13
0.96
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
6.26
17.94
20.13
23.35
32.47
42.75
58.22
58.5
57.77
57.3
72.03
77.73
- -
Book Value per Share
- -
6.26
17.94
20.13
23.35
32.47
42.75
58.22
58.5
55.15
55.2
68.83
73.91
- -
Tangible Book Value per Share
9
9
3
8
8
8
8
8
8
8
8
10
10
10
Basic Weighted Avg Shares
960
1,058
992
1,067
1,122
1,558
1,672
1,816
2,000
1,830
1,972
1,595
1,963
1,908
Sales/Revenue/Turnover
13.19
5.38
3.61
3.83
4.46
9.89
11.75
11.03
2.14
-1.46
3.01
1.5
7.48
6.89
Operating Margin (%)
23
27
27
24
27
28
32
34
38
45
58
60
65
66
Depreciation Expense
9
17
2
14
17
75
109
137
11
-2
1
-13
55
53
Net Income, GAAP
20.95
19.87
18.14
24.13
27.5
39.09
22.68
20.6
34.24
302.67
77.2
- -
31.07
29.09
Effective Tax Rate (%)
0.9
1.56
0.18
1.27
1.53
4.82
6.52
7.55
0.57
-0.1
0.07
-0.81
2.83
2.75
Profit Margin (%)
- -
-77
-114
-141
-93
-43
51
119
53
-51
-107
80
152
- -
Working Capital
- -
113
48
58
74
74
46
70
133
123
146
92
73
- -
LT Debt
- -
58
60
161
187
260
342
466
468
462
458
699
755
- -
Total Equity
- -
- -
7.91
10.54
8.89
19.87
25.13
25.22
3.52
-5.28
1.41
- -
8.04
- -
Return on Invested Capital (%)
- -
- -
5.37
9.03
7.62
19.16
24.34
24.94
3.61
-6.59
1.23
- -
7.85
- -
Return on Capital (%)
- -
- -
3.06
12.25
9.86
33.63
36.22
33.96
2.45
-0.39
0.3
-2.23
7.63
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
427
- -
LT Borrowings
- -
73
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
4,912
1,976
2,428

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,674
- -
Cash, Cash Equivalents & STI
- -
6
- -
Accounts Receivable, Net
- -
1,162
- -
Inventories
- -
448
- -
Total Current Liabilities
- -
1,522
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
427
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
35.05%
11.79%
7.91%
Free Cash Flow
36.71%
-200.29%
-108.69%
Net Income, GAAP
-85.59%
-388.16%
-529.86%
Sales/Revenue/Turnover
8.08%
2.67%
23.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
324
440
421
409
1,595
2026
538
510
426
487
1,963
2027
484
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-7.61
0.93
1.42
3
-1.33
2026
1.45
1.19
0.37
2.69
5.7
2027
1.15
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Everest Organics Limited manufactures and sells active pharmaceutical ingredients, intermediates, and key starting materials for the global pharmaceutical industry from its USFDA-approved facility in Sadasivpet near Hyderabad, India. Founded in 1993 and headquartered in Hyderabad, the company offers a portfolio of more than 30 APIs across therapeutic categories including gastroenterology, hypercholesterolemia, anti-convulsants, anti-thrombotics, and anti-fungals, such as omeprazole, ciprofloxacin, rabeprazole sodium, apixaban, aprepitant, and bilastine; it also provides over 32 customized intermediates and key starting materials, along with contract research and manufacturing services encompassing co-development, custom synthesis, and contract development and manufacturing organization offerings. The company exports to Europe, the United States, the Far East, the Middle East, and Latin America, serving multinational pharmaceutical firms and formulation companies with products compliant to BP, USP, EP, and IP pharmacopoeial standards. In recent developments, Everest Organics expanded into contract development and manufacturing organization and contract manufacturing organization services during fiscal year 2024-25, alongside facility upgrades to current good manufacturing practices standards and dedicated investments in new production capacities and scientific teams for advanced chemistry zones; it also secured Korea Drug Master File approval for rabeprazole sodium API and reported unaudited financial results for quarters through June 2025, reflecting strategic progress amid industry challenges.